Publication | Open Access

Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial

Prognostic BiomarkersMedicineRandomised Phase 3PathologyCancer GenomicsPredictive ValueBronchial NeoplasmMolecular DiagnosticsOncologyRadiation OncologyLung CancerProteomic Signature